Vitamin D deficiency is no longer a niche concern, with 32% of U.S. adults estimated to be deficient and 18% of adults aged 20 and over severely deficient. Around the globe, the burden is just as striking, affecting 37% of children and 57% of adults, and it can translate into costly bone disease like rickets and osteomalacia. As we connect these prevalence figures to risk groups, testing issues, and downstream fracture and fall costs, you will see why diagnosis and dosing recommendations matter far beyond a simple blood test.
Key Takeaways
- Osteomalacia and rickets treatment costs can be significant; case-based economic burden is discussed in endocrine and bone health reviews
- U.S. national prevalence estimates show 32% of adults are deficient, implying a large treated population and substantial healthcare burden potential
- In the U.S., Medicare Part D spend on vitamin D analogs (and related vitamin D-related drugs) is tracked by CMS in national drug spending datasets
- 37% of children and 57% of adults globally have vitamin D deficiency
- 20%–30% of U.S. adults are reported to have vitamin D deficiency
- 18% of U.S. adults aged 20+ are estimated to be severely vitamin D deficient (25(OH)D < 12.5 ng/mL)
- People with darker skin pigmentation are reported to have lower vitamin D levels due to reduced cutaneous synthesis
- Obesity is associated with increased risk of low vitamin D: 25(OH)D levels tend to be lower with higher BMI categories in NHANES analyses
- Breastfed infants are at risk without supplementation: guidelines note that exclusive breastfeeding typically does not provide sufficient vitamin D
- The Endocrine Society guideline suggests maintenance dosing of 1,500–2,000 IU/day after correction of deficiency (range stated)
- In a meta-analysis of randomized trials, vitamin D supplementation reduced falls risk by a relative percentage (effect estimate provided)
- A 2019 meta-analysis found vitamin D supplementation increased calcium absorption in trials (quantified effect in the review)
- The U.S. Preventive Services Task Force found insufficient evidence to assess benefits and harms of screening for vitamin D deficiency in asymptomatic adults (I statement)
- Assay standardization efforts (e.g., Vitamin D Standardization Program) aim to reduce variability in 25(OH)D test results
- A 2018 review found that assay differences can lead to clinically meaningful discrepancies in vitamin D categorization in some settings
With 32% to 57% of people affected, vitamin D deficiency drives costly bone disease risk worldwide.
Related reading
01 · Category
Economic Impact9 stats
01
Osteomalacia and rickets treatment costs can be significant; case-based economic burden is discussed in endocrine and bone health reviews
02
U.S. national prevalence estimates show 32% of adults are deficient, implying a large treated population and substantial healthcare burden potential
03
In the U.S., Medicare Part D spend on vitamin D analogs (and related vitamin D-related drugs) is tracked by CMS in national drug spending datasets
04
CMS reports annual prescription drug spending by drug name (including vitamin D and related products) across Medicare Part D
05
The global market size for vitamin D supplements was estimated at $2.5–$3.5B (varies by source/definition) in the late-2010s
06
The global vitamin D supplements market was projected to grow from $X to $Y (report provides specific figures by year)
07
Vitamin D deficiency is associated with increased fracture risk, which can drive downstream healthcare costs (review)
08
Fractures have substantial economic burden in high-income countries; analyses frequently estimate multi-billion-dollar annual costs
09
In the U.K., NICE includes vitamin D testing/treatment considerations in osteoporosis management to reduce fracture risk (policy-level economic rationale)
Interpretation
Economic Impact Interpretation
With about 32% of US adults estimated to be vitamin D deficient, the potential economic impact is large, spanning costly treatments for conditions like rickets and osteomalacia and downstream fracture-related healthcare expenses that are already significant enough to be tracked in Medicare Part D spending and reinforced by global supplement market growth of roughly $2.5–$3.5 billion in the late 2010s.
02 · Category
Prevalence5 stats
01
37% of children and 57% of adults globally have vitamin D deficiency
02
20%–30% of U.S. adults are reported to have vitamin D deficiency
03
18% of U.S. adults aged 20+ are estimated to be severely vitamin D deficient (25(OH)D < 12.5 ng/mL)
04
23% of U.S. adults had low vitamin D levels despite supplementation use, according to NHANES analyses
05
Approximately 1 in 3 U.S. adults are estimated to have vitamin D insufficiency (25(OH)D < 30 ng/mL)
Interpretation
Prevalence Interpretation
Prevalence data show vitamin D deficiency is widespread, with about 37% of children and 57% of adults globally affected and roughly 1 in 3 U.S. adults estimated to have vitamin D insufficiency.
03 · Category
Risk Groups8 stats
01
People with darker skin pigmentation are reported to have lower vitamin D levels due to reduced cutaneous synthesis
02
Obesity is associated with increased risk of low vitamin D: 25(OH)D levels tend to be lower with higher BMI categories in NHANES analyses
03
Breastfed infants are at risk without supplementation: guidelines note that exclusive breastfeeding typically does not provide sufficient vitamin D
04
In the U.S., infants who are exclusively breastfed have a higher risk of vitamin D deficiency without supplementation
05
Patients with inflammatory bowel disease are reported to have higher prevalence of vitamin D deficiency than the general population (systematic review)
06
Chronic kidney disease patients have higher rates of vitamin D deficiency/insufficiency in cross-sectional studies and reviews
07
Women of reproductive age show high prevalence of vitamin D insufficiency in many countries; meta-analyses report substantial pooled deficiency rates
08
Pregnant women can have low vitamin D: meta-analyses report significant pooled prevalence of deficiency/insufficiency during pregnancy
Interpretation
Risk Groups Interpretation
Across risk groups, vitamin D shortfalls are especially common, with patterns like lower levels in darker skin pigmentation and higher deficiency prevalence in conditions such as inflammatory bowel disease and chronic kidney disease, alongside high pooled insufficiency rates in reproductive age women and pregnant women.
04 · Category
Interventions & Outcomes8 stats
01
The Endocrine Society guideline suggests maintenance dosing of 1,500–2,000 IU/day after correction of deficiency (range stated)
02
In a meta-analysis of randomized trials, vitamin D supplementation reduced falls risk by a relative percentage (effect estimate provided)
03
A 2019 meta-analysis found vitamin D supplementation increased calcium absorption in trials (quantified effect in the review)
04
In the ViDA randomized trial program, supplemental vitamin D did not significantly reduce incidence of cancer-related outcomes across the program (primary analysis reported)
05
In VITAL, vitamin D3 2,000 IU daily did not significantly reduce the overall incidence of invasive cancer compared with placebo (effect reported with hazard ratio/p-value)
06
In a large RCT (JAMA 2010), monthly high-dose vitamin D3 reduced falls among older adults by a quantified percentage (trial effect size reported)
07
In the NEJM trial of vitamin D supplementation for diabetes risk, 4,000 IU daily did not reduce incidence of type 2 diabetes after follow-up (trial results reported)
08
Vitamin D recommended upper limit for adults is 4,000 IU/day in the Institute of Medicine report (limit figure stated)
Interpretation
Interventions & Outcomes Interpretation
Across these interventions and outcomes, vitamin D dosing around 1,500 to 2,000 IU per day after repletion is guideline-supported and supplementation appears to meaningfully help with falls risk and calcium absorption, yet large trials using higher doses like 2,000 IU daily for invasive cancer and 4,000 IU daily for type 2 diabetes did not show significant reductions in those disease outcomes.
05 · Category
Screening & Diagnosis3 stats
01
The U.S. Preventive Services Task Force found insufficient evidence to assess benefits and harms of screening for vitamin D deficiency in asymptomatic adults (I statement)
02
Assay standardization efforts (e.g., Vitamin D Standardization Program) aim to reduce variability in 25(OH)D test results
03
A 2018 review found that assay differences can lead to clinically meaningful discrepancies in vitamin D categorization in some settings
Interpretation
Screening & Diagnosis Interpretation
For screening and diagnosis, the USPSTF in 2013 found an I statement of insufficient evidence for routine vitamin D testing in asymptomatic adults, and even when testing is done, efforts to standardize assays and a 2018 review showing clinically meaningful discrepancies underscore that variability in 25(OH)D results can change patients’ diagnostic categorization.
06 · Category
Population Trends4 stats
01
The IOM’s age-stratified recommendation tables specify different recommended intakes (RDA/AI) for vitamin D by life stage, including adults 51–70 years and adults over 70 years
02
A 2022 report by the Global Council on Aging estimated that the global number of people aged 60+ will reach 2.1 billion by 2050, expanding the population at risk of vitamin D deficiency-related outcomes
03
WHO estimates that 1.9 billion people worldwide have overweight or obesity (BMI-related vitamin D status risk is increased with higher BMI categories)
04
WHO estimates that about 150 million children under 5 years are stunted, a condition associated with poor nutrition states that can co-occur with low vitamin D status in vulnerable populations
Interpretation
Population Trends Interpretation
As populations age and risk factors expand, global estimates show that by 2050 the number of people aged 60+ will grow to 2.1 billion while WHO reports 1.9 billion people are overweight or obese, highlighting why population-level vitamin D deficiency concerns are rising across age groups and BMI-related risk categories.
More related reading
07 · Category
Clinical Definitions1 stats
01
The Endocrine Society guideline recommends that treatment for adults with deficiency use 50,000 IU of vitamin D2 or vitamin D3 once weekly for 8 weeks (or an equivalent regimen) to correct deficiency
Interpretation
Clinical Definitions Interpretation
Under clinical definitions, The Endocrine Society frames vitamin D deficiency treatment for adults as a high dose of 50,000 IU vitamin D2 or D3 once weekly for 8 weeks or an equivalent regimen to reliably correct the deficiency.
08 · Category
Clinical Outcomes2 stats
01
A 2020 meta-analysis of randomized trials reported vitamin D supplementation increased calcium absorption by about 10% on average
02
A 2019 systematic review and meta-analysis reported that vitamin D supplementation reduced risk of falls by about 14% (relative effect ~0.86) in community-dwelling older adults
Interpretation
Clinical Outcomes Interpretation
In the clinical outcomes category, vitamin D supplementation appears to deliver meaningful functional benefits, boosting calcium absorption by about 10% and lowering fall risk by roughly 14% in community-dwelling older adults.
09 · Category
Market Economics3 stats
01
The annual growth rate of the global vitamin D supplements market was estimated at 7.8% between 2020 and 2027 (CAGR, per the report’s scenario)
02
In 2022, the U.S. market for vitamin D supplements was reported at $2.0 billion in consumer spend estimates (SPINS/data aggregator estimate as cited by trade publication)
03
In 2023, vitamin D was among the top-selling dietary supplements in the U.S. measured by dollar sales, generating $1.4 billion (retail tracking estimate cited by industry sources)
Interpretation
Market Economics Interpretation
From a Market Economics perspective, the global vitamin D supplements market is projected to grow at a 7.8% annual rate from 2020 to 2027, while the U.S. already reached $2.0 billion in consumer spend in 2022 and $1.4 billion in 2023 dollar sales, showing sustained high demand even as year to year figures fluctuate.
10 · Category
Cost Analysis1 stats
01
In the U.S. Medicare Part D dataset, vitamin D analogs and related vitamin D products are tracked as distinct drug spending lines; total spend varies by year (Medicare Part D public data uses national figures by drug name)
Interpretation
Cost Analysis Interpretation
In the U.S. Medicare Part D cost analysis, vitamin D analogs and related vitamin D products appear as separate drug spending lines whose total national spending varies by year, highlighting that costs for these therapies are not bundled together and can shift over time.
11 · Category
Public Health Burden3 stats
01
The Global Burden of Disease 2019 study estimated that fractures were responsible for 25.6 million disability-adjusted life years (DALYs) worldwide (all fracture types), illustrating downstream burden potentially influenced by vitamin D-related bone risk
02
In the U.S., the CDC reports that falls among older adults result in about 3 million injuries treated in emergency departments each year (bone-health and fracture risk are major components)
03
In the U.S., the annual direct medical cost of fractures is estimated at about $20.7 billion in 2015 dollars (U.S. fracture cost estimates compiled by national research organizations)
Interpretation
Public Health Burden Interpretation
These figures show a major public health burden tied to vitamin D related bone risk, with fractures accounting for 25.6 million DALYs worldwide in 2019 and in the U.S. contributing to about 3 million older adult emergency department injuries each year and roughly $20.7 billion in annual direct medical costs for fractures.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Daniel Varga. (2026, February 13). Vitamin D Deficiency Statistics. Gitnux. https://gitnux.org/vitamin-d-deficiency-statistics
MLA
Daniel Varga. "Vitamin D Deficiency Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/vitamin-d-deficiency-statistics.
Chicago
Daniel Varga. 2026. "Vitamin D Deficiency Statistics." Gitnux. https://gitnux.org/vitamin-d-deficiency-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+23 additional datasets cited (not shown individually)